EAST ASIA
Featured Article
ITRI subscribed to Thomson Reuters Pharma in 2007 because it provides both technical and commercial information and covers many compounds which are in different development stages (discovery, preclinical, clinical, launched, or discontinued) while other information providers only deliver sections of the information we need.